Launch of new safety hypodermic needle
Heart disease patients living in poorer areas of B.C. are up to twice as likely to die from chronic diseases than patients living in better-off areas, a University of British Columbia study has found. The research, released this week in the online journal Public Library of Science ONE , found coronary-artery disease patients living in
Full Post: Mortality rates higher for heart disease patients in neighbourhoods with poor socioeconomics status
Covidien has announced that it is launching a new and improved Magellan Safety Hypodermic Needle.
The development of the new design, which gives clinicians more control and smoother activation of the safety shield, reflects Covidien’s continued commitment to improving healthcare worker safety.
“We are transitioning to the new and improved Magellan Safety Needle technology as part of our strong and ongoing commitment to meeting the safety needs of our customers,” said Jeff Hunt, President, Patient Care and Safety Products, Covidien. “As you may know, there is litigation under way related to the current Magellan Safety Needle technology used on our Magellan family of products. We are optimistic that the litigation will ultimately be resolved in our favor,” Hunt added.
Covidien also announced that it has appealed a U.S. District Court jury finding in November 2007 that Covidien’s current Magellan Safety Needle products infringed one of Becton Dickinson’s patents and a subsequent judge’s ruling granting Becton Dickinson’s request for an injunction against Covidien’s current Magellan Safety Needle product line. The injunction is scheduled to take effect on December 17, 2008. Over the next several weeks, Covidien will transition from its current line to its new and improved Safety Needle products.
“While we respect the judge’s recent ruling in this matter, we believe our current product line does not infringe on Becton Dickinson’s intellectual property,” Hunt said. “Our number one priority is to ensure that our customers receive the very best in needle safety protection. We will continue to provide the best solutions in healthcare worker protection as we seamlessly transition to the new and improved Magellan Safety Needles.”
Net sales of the Magellan product line were less than $35 million in fiscal 2008.
Synerx Pharma, LLC has announced the submission to the FDA of Isosulfan Blue Injection (generic equivalent to Lymphazurin, Covidien (formerly US Surgical)). This ANDA submission is the culmination of a four year joint effort by Synerx Pharma, LLC and its exclusive raw material supplier Apicore, LLC. According to Synerx Pharma and Apicore, the active ingredient
Full Post: Synerx Pharma announces FDA submission of Isosulfan Blue injection ANDA
Watson Pharmaceuticals, Inc. has received approval from the United States Food and Drug Administration to market its over-the-counter Nicotine Polacrilex Gum USP, coated mint flavor, in the 2 mg and 4 mg strengths. Nicotine Polacrilex Gum, coated mint flavor, is the generic equivalent of GlaxoSmithKline Consumer Healthcare’s Nicorette (R) fresh mint gum, which is used
Full Post: Watson Pharmaceuticals receives FDA approval for mint coated nicotine gum
Antares Pharma, Inc. today announced that its license partner, Ferring Pharmaceuticals has received additional regulatory approvals in Europe and Australia for use of Antares’ needle-free injection devices with its human growth hormone (hGH), Zomacton. Ferring has been notified recently that the mutual recognition process for European member states has been positively concluded for the Zomacton
Full Post: Needle-free injection device approved in Europe and Australia
BD Diagnostics, a segment of BD (Becton, Dickinson and Company) has announced that it received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for the BD FocalPoint(TM) GS Imaging System. This innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath(TM) Pap test slides to detect evidence
Full Post: BD Diagnostics receives FDA approval for imaging system that enhances detection of cervical cancer
Arteriocyte announced today a $1,950,000 award from DARPA for the company’s Nanofiber Based System (NANEX) technology for the Production of Red Blood Cells project. DARPA’s Blood Pharming program aims to develop an automated culture and packaging system that will yield a readily available, donorless supply of universal donor red blood cells in the military
Full Post: Arteriocyte awarded DARPA funding for company’s blood pharming technology